The California Office of Statewide Health Planning and Development recently released the nation’s first mandatory data on wholesale acquisition cost increases for prescription drugs. The state this year began requiring drug makers to report WAC increases for drugs when they exceed 16% over two years, including the reasons for the increases if publicly available. The three-year median increase for drug makers submitting data in first-quarter 2019 was 25.8%. Generic drugs experienced the largest median increase at 37.6% overall and 156.4% for those under $100. Brand name drugs with a wholesale cost greater than $10,000 rose a median 30.4%. More than two-thirds of those submitting data did not provide reasons for the price increases.
 

Related News Articles

Blog
A recent report from UnitedHealth comparing specialty drug spending in hospitals and independent physician offices fails to account for critical differences…
Headline
The House Energy and Commerce Committee today approved legislation to address surprise medical bills and Medicaid disproportionate share hospital cuts.
Headline
A federal judge yesterday struck down a Centers for Medicare…
Headline
The House Energy and Commerce Subcommittee on Health today held a hearing on seven bills aimed at improving transparency in the drug supply chain to lower…
Headline
The Centers for Medicare…
Headline
The largest U.S. pharmaceutical and biotech companies spend just 22 cents out of every dollar on research and development, according to an analysis released…